Speak to the pharma team
01628 581 240
Speak to the healthcare team
01225 336 335
Speak to the clinical team
01628 581 240
Speak to the contract team
01225 336 335
Speak to us about Master Vendor
01225 336 335
Or send your enquiry via email and the best person to help will be in touch.
solutions@starmedical.co.uk
Nordisk was established in Denmark in 1923 by Nobel Prize winner August Krogh and Dr H C Hagedorn when, funded by Danish pharmacist August Kongsted, they succeeded in extracting a small quantity of insulin from a bovine pancreas to treat patients with diabetes. Brothers Harald and Thorvald Pedersen joined Nordisk to engineer machines for insulin production and after leaving in 1924, they set up their own company, Novo, selling insulin and syringes.
Both Novo and Nordisk expanded rapidly and successfully, with Novo becoming the world's largest producer of industrial enzymes and Nordisk developing drugs to treat haemophilia and growth disorders. In 1989 the two companies merged to concentrate on conquering world markets for the development of new diabetes treatments. In 1999 they de-merged into two businesses Healthcare and Enzymes, creating Novo Nordisk and Novozymes.
Novo Nordisk is now present across Europe, Japan, Oceania and North America.
Novo Nordisk specialises in diabetes and has the broadest portfolio in the industry. They also have products in the following therapeutic areas Hormone replacement therapy, Haemostasis management and Growth hormone therapy.
Insulin analogues Levemir, NovoRapid, NovoMix
Human insulin Actrapid, Mixard, Insulatard, Velosulin
Insulin delivery devices FlexPen, Innolet, NovoPen
Needles NovoFine
Hormone replacement therapy:
Kilovance, Novoferm, Vagifem
Growth hormone therapy:
Devices NordiPen and NordiPenMate
Growth hormone Norditropin SimpleXx
